Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group

Pol Arch Intern Med. 2020 Mar 27;130(3):255-257. doi: 10.20452/pamw.15224. Epub 2020 Mar 3.
No abstract available

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Hypereosinophilic Syndrome / drug therapy*
  • Hypereosinophilic Syndrome / genetics
  • Imatinib Mesylate / therapeutic use*
  • Male
  • Middle Aged
  • Mutation*
  • Oncogene Proteins, Fusion*
  • Poland
  • Protein Kinase Inhibitors
  • Receptor, Platelet-Derived Growth Factor alpha*
  • Treatment Outcome
  • Young Adult
  • mRNA Cleavage and Polyadenylation Factors*

Substances

  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • mRNA Cleavage and Polyadenylation Factors
  • Imatinib Mesylate
  • FIP1L1-PDGFRA fusion protein, human
  • Receptor, Platelet-Derived Growth Factor alpha